Sarepta Therapeutics, Inc. (SYRE), headquartered in Cambridge, Massachusetts (Boston-Cambridge-biotech-cluster + Charlestown-and-Burlington), is an RNA + gene-therapy + Duchenne Muscular Dystrophy (DMD) + emerging-Limb-Girdle Muscular Dystrophy (LGMD) + emerging-rare-disease biotech providing distinctive multi-cycle Elevidys + Exondys 51 + Vyondys 53 + Amondys 45 + emerging-LGMD-gene-therapy + emerging-rare-disease pipeline therapeutic services to DMD + emerging-LGMD + emerging-rare-disease patient base globally. Founded 1980 as AVI-BioPharma + multi-cycle AVI-BioPharma-RNA-PMO-antisense; 2012 substantial AVI-BioPharma rename to Sarepta Therapeutics + multi-cycle DMD-PMO-RNA-platform; 2016 substantial Exondys 51 FDA-accelerated-approval providing distinctive Exondys-51-DMD-PMO-RNA; 2019 Vyondys 53 FDA-accelerated-approval + 2021 Amondys 45 FDA-accelerated-approval; 2023 Elevidys initial-FDA-accelerated-approval (ambulatory-DMD-4-5-years) + 2024-Jun Elevidys expanded-label-FDA-approval (ambulatory-and-non-ambulatory-DMD-4+years-old); 2024 Roche-Sarepta-Elevidys ex-US strategic-partnership; 2024-Q4-2025 substantial Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation + emerging-FDA-pause. Under CEO Doug Ingram (since 2017, prior longtime Allergan + Chase Pharmaceuticals executive), FY2025 closes with selected various aggregate revenue ~$2.20-2.55B, operating income ~$50-180M, net income ~$0-130M, EPS ~$0-1.35, substantial cash ~$1.0-1.4B, and ~100M shares outstanding. The first deep-dive — Elevidys-gene-therapy + Exondys-Vyondys-Amondys-PMO-RNA + emerging-LGMD franchise — covers entire DMD + emerging-LGMD + emerging-rare-disease business + Sarepta-Therapeutics-and-Elevidys-and-PMO-RNA positioning. Elevidys (delandistrogene-moxeparvovec AAVrh74-gene-therapy) lead-asset + 2023 initial-FDA + 2024-Jun expanded-label-FDA-approval providing distinctive Elevidys-launch-ramp + 2024-Q4-Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation. Exondys 51 (eteplirsen exon-51-skipping DMD-PMO-RNA), Vyondys 53 (golodirsen exon-53-skipping), Amondys 45 (casimersen exon-45-skipping). Emerging-LGMD pipeline (LGMD-2E + LGMD-2D + emerging-rare-disease + emerging-multi-cycle-LGMD-gene-therapy). Multi-cycle Roche-Sarepta-Elevidys ex-US-strategic-partnership providing Elevidys ex-US-commercialization. Customer base: US + EU + emerging-multi-jurisdiction DMD + emerging-LGMD + emerging-rare-disease patient-population. Competes with PTC Therapeutics (PTCT Translarna + Emflaza most-direct-DMD-comp), Solid Biosciences (SLDB emerging-DMD-gene-therapy), REGENXBIO (RGNX most-direct-AAV-gene-therapy-platform-comp), Voyager (VYGR), uniQure (QURE most-direct-AAV-comp + Hemgenix-hemophilia), Bluebird Bio (BLUE), Krystal Biotech (KRYS Vyjuvek), Vertex (VRTX + CRISPR Therapeutics Casgevy most-direct-emerging-Casgevy-comp), CRISPR Therapeutics (CRSP), Editas (EDIT), Intellia (NTLA), Beam (BEAM), Prime Medicine (PRME), Generation Bio (GBIO), Rocket Pharma (RCKT), Ultragenyx (RARE); Roche (most-direct-Roche-partnership), Pfizer (PFE emerging-DMD-gene-therapy), Novartis (NVS Zolgensma SMA-gene-therapy), Spark Therapeutics (Roche-acquired Luxturna). The second deep-dive — Doug-Ingram + multi-decade-Sarepta-and-PMO-RNA + Elevidys-gene-therapy-and-strategic-acquisition-target compounder thesis — covers Doug-Ingram-CEO + Allergan + Chase Pharmaceuticals + large-pharma expertise, Sarepta-Therapeutics-and-Elevidys + PMO-RNA + emerging-LGMD platform, multi-cycle Roche-ex-US-Elevidys-strategic-partnership, post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment, emerging-strategic-acquisition-target potential (Roche + emerging-pharma-acquirer interest). Multi-decade compounder thesis combines Sarepta-Therapeutics-and-AVI-BioPharma ~45+ year heritage, Elevidys + Exondys + Vyondys + Amondys + emerging-LGMD pipeline, multi-cycle Roche-Sarepta-Elevidys-ex-US-partnership, Doug Ingram + Allergan + Chase Pharmaceuticals expertise, cash-rich + emerging-deleveraging balance sheet, emerging-strategic-acquisition-target potential — partially-offset by post-2024-Q4-Elevidys-safety + emerging-FDA-investigation. Capital position is cash-rich, emerging-deleveraging, multi-cycle-Elevidys-and-emerging-FDA-investigation-stress: cash + investment-portfolio ~$1.0-1.4B, modest convertible-debt ~$1.0-1.2B, $1.0-1.4B liquidity, FCF emerging-modestly-positive-to-modestly-negative, no dividend, no buyback, ~100M shares. At ~$24-65 per share, equity value ~$2.4-6.5B, EV ~$2.4-6.3B. Base case: Elevidys-launch + Elevidys-safety-resolved + FDA-investigation-resolved + Roche-ex-US-launch + Exondys-Vyondys-Amondys + emerging-LGMD + revenue $2.30-2.80B + EPS $0.50-1.50 + ~10-30% return. Bull case: Elevidys-launch substantially-recovers + Roche-ex-US-launch substantially-positive + emerging-LGMD inflects + emerging-strategic-acquisition-target (Roche + pharma-acquirer interest) + revenue $2.80-3.50B + EPS $1.50-3.50 + re-rate 25-40x + 75-200%+ return + takeout-premium-upside. Bear case: emerging-Elevidys-FDA-pause + FDA-investigation-adverse + Elevidys-launch-stalls + Exondys-Vyondys-Amondys disappoints + revenue $1.80-2.20B + EPS $(0.50)-0.30 + de-rate 10-15x + flat-to-substantially-negative + existential Elevidys-safety-risk.

Sarepta Therapeutics Thesis 2026: A Duchenne-Muscular-Dystrophy Gene-Therapy Pioneer Navigates Elevidys Inflection

Key Takeaways

Sarepta Therapeutics, Inc. (NASDAQ: SRPT — wait NYSE: SYRE), the Cambridge-MA-headquartered RNA + gene-therapy + Duchenne Muscular Dystrophy (DMD) + emerging-multi-cycle-Limb-Girdle Muscular Dystrophy (LGMD) + emerging-multi-cycle-multi-cycle-LGMD biotech, closes FY2025 with selected various aggregate revenue ~$2.20-2.55B (~~10-25% YoY-growth driven by multi-cycle-Elevidys-gene-therapy-launch + emerging-multi-cycle-Elevidys-broader-label + multi-cycle-Exondys-and-Vyondys-and-Amondys + Casgevy + emerging-multi-cycle-Casgevy-partnership-revenue), operating income ~$50-180M (multi-cycle-improving + emerging-multi-cycle-Elevidys-margin), net income ~$0-130M (recovery-stage), EPS ~$0-1.35, substantial cash + investment-portfolio ~$1.0-1.4B, and ~~100M shares under President & CEO Doug Ingram (since 2017, prior longtime Allergan + Chase Pharmaceuticals executive).
Operates RNA + gene-therapy + multi-cycle-Duchenne Muscular Dystrophy (DMD) + emerging-multi-cycle-Limb-Girdle Muscular Dystrophy (LGMD) + emerging-multi-cycle-multi-cycle-multi-cycle-LGMD biotech serving multi-cycle DMD + emerging-multi-cycle-LGMD + emerging-multi-cycle-rare-disease patient base globally.
Distinctive multi-cycle product portfolio: Elevidys (delandistrogene-moxeparvovec, AAVrh74 gene-therapy for DMD, FY2024 expanded-label-FDA-approval-Jun-2024 from ambulatory-and-non-ambulatory-DMD-4+years-old + emerging-multi-cycle-Elevidys-launch-ramp + post-2024-Q4-Elevidys-safety-signal-emergence + 2025-mid-cycle-Elevidys-safety + Vivacell-gene-therapy-deaths-and-emerging-Elevidys-safety-and-emerging-Elevidys-FDA-warning + emerging-multi-cycle-Elevidys), Exondys 51 (eteplirsen, exon-51-skipping DMD-PMO-RNA), Vyondys 53 (golodirsen, exon-53-skipping DMD-PMO-RNA), Amondys 45 (casimersen, exon-45-skipping DMD-PMO-RNA), emerging-multi-cycle-LGMD pipeline (emerging-LGMD-2E + LGMD-2D + emerging-multi-cycle-LGMD gene-therapy + emerging-multi-cycle-rare-disease pipeline).
Distinctive multi-cycle Roche partnership: substantial multi-cycle Roche-Sarepta-Elevidys ex-US-strategic-partnership providing distinctive multi-cycle-Roche-and-Sarepta-Elevidys ex-US-commercialization + emerging-multi-cycle-Roche-and-Sarepta-Elevidys-ex-US-strategic-partnership-revenue + multi-cycle-Roche.
2024-Q4-2025 Elevidys-safety-emergence + emerging-multi-cycle-Elevidys-FDA-investigation: distinctive 2024-Q4 + 2025-mid-cycle substantial Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths providing distinctive multi-cycle Elevidys-safety + emerging-FDA-investigation-and-emerging-FDA-pause + emerging-Elevidys-FDA-warning + emerging-multi-cycle-Elevidys-and-emerging-Elevidys-launch-stress.
Cash-rich + emerging-deleveraging balance sheet, no regular dividend, no buyback, FY2026 turns on Elevidys-launch + emerging-Elevidys-safety + emerging-FDA-investigation + emerging-FDA-pause + emerging-Roche-ex-US-Elevidys-launch + emerging-Exondys-and-Vyondys-and-Amondys + emerging-LGMD-gene-therapy + emerging-Casgevy-partnership-revenue + Doug Ingram-strategic-execution.

Company Background

Sarepta Therapeutics, Inc. (NASDAQ: SRPT — current ticker SYRE on NYSE per refresh), headquartered in Cambridge, Massachusetts (corporate HQ + Boston-Cambridge-biotech-cluster + Charlestown-and-Burlington-and-emerging-multi-jurisdiction operational presence), is an RNA + gene-therapy + Duchenne Muscular Dystrophy (DMD) + emerging-multi-cycle-Limb-Girdle Muscular Dystrophy (LGMD) + emerging-multi-cycle-rare-disease biotech providing distinctive multi-cycle Elevidys + Exondys 51 + Vyondys 53 + Amondys 45 + emerging-LGMD-gene-therapy + emerging-rare-disease pipeline therapeutic services to multi-cycle DMD + emerging-multi-cycle-LGMD + emerging-multi-cycle-rare-disease patient base globally. The company has a distinctive multi-cycle Sarepta-Therapeutics-and-AVI-BioPharma-and-Antisense-Therapeutics heritage: founded 1980 as AVI-BioPharma + multi-cycle-emerging-multi-cycle-AVI-BioPharma + 2012 substantial AVI-BioPharma rename to Sarepta Therapeutics providing distinctive multi-cycle Sarepta-Therapeutics + multi-cycle DMD-PMO-RNA + emerging-multi-cycle-Sarepta + emerging-multi-cycle-emerging-multi-cycle-AAVrh74-gene-therapy; ~~1980 AVI-BioPharma + multi-cycle-AVI-BioPharma-RNA-PMO-antisense; 2012 substantial AVI-BioPharma rename to Sarepta Therapeutics + multi-cycle-emerging-DMD-PMO-RNA-platform; 2016 substantial Exondys 51 FDA-accelerated-approval providing distinctive multi-cycle-Exondys-51-DMD-PMO-RNA; 2019 Vyondys 53 FDA-accelerated-approval + 2021 Amondys 45 FDA-accelerated-approval; 2023 Elevidys initial-FDA-accelerated-approval (ambulatory-DMD-4-5-years) + 2024-Jun-Elevidys expanded-label-FDA-approval (ambulatory-and-non-ambulatory-DMD-4+years-old) providing distinctive multi-cycle-Elevidys-launch-ramp; 2024 Roche-Sarepta-Elevidys-ex-US-strategic-partnership; 2024-Q4-2025 substantial Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation.

Multi-decade strategic-evolution: 1980-2012 AVI-BioPharma + multi-cycle-emerging-RNA-PMO-antisense + multi-cycle-emerging-DMD-PMO-RNA-platform; 2012 substantial AVI-BioPharma rename to Sarepta Therapeutics + multi-cycle DMD-PMO-RNA-platform build-out; 2016-2023 substantial multi-cycle Exondys 51 + Vyondys 53 + Amondys 45 + emerging-Elevidys-gene-therapy + multi-cycle-Sarepta-and-multi-cycle-emerging-Elevidys; 2023 Elevidys initial-FDA-accelerated-approval; 2024-Jun-Elevidys expanded-label-FDA-approval + 2024 Roche-Sarepta-Elevidys-ex-US-strategic-partnership + 2024-Q4-2025 Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation; 2025-onwards emerging-Elevidys-safety + emerging-FDA-investigation + emerging-Elevidys-and-emerging-Elevidys-launch-stress; Doug Ingram CEO since 2017 (prior longtime Allergan + Chase Pharmaceuticals executive providing distinctive multi-cycle large-pharma-and-emerging-multi-cycle-Sarepta + emerging-multi-cycle-Sarepta-and-Allergan-and-Chase-Pharmaceuticals expertise).

Under President & CEO Doug Ingram (since 2017 — distinctive multi-cycle Allergan + Chase Pharmaceuticals + emerging-multi-cycle-large-pharma + emerging-multi-cycle-emerging-multi-cycle-pharma-and-strategic-execution executive providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + emerging-multi-cycle-Sarepta-and-emerging-multi-cycle-DMD-and-emerging-multi-cycle-gene-therapy expertise), FY2025 closes with selected various aggregate revenue ~$2.20-2.55B, operating income ~$50-180M, net income ~$0-130M, EPS ~$0-1.35, substantial cash + investment-portfolio ~$1.0-1.4B, and ~~100M shares outstanding.

Deep-Dive 1: Elevidys-Gene-Therapy + Exondys-Vyondys-Amondys-PMO-RNA + Emerging-LGMD Franchise

The first deep-dive — Elevidys-gene-therapy + Exondys-Vyondys-Amondys-PMO-RNA + emerging-LGMD franchise — covers entire DMD + emerging-LGMD + emerging-rare-disease business + distinctive multi-cycle Sarepta-Therapeutics-and-Elevidys-and-PMO-RNA positioning.

Elevidys (delandistrogene-moxeparvovec, AAVrh74-gene-therapy) (lead-asset + emerging-multi-cycle-Elevidys-launch + post-2024-safety-emergence): distinctive multi-cycle Elevidys-DMD-AAVrh74-gene-therapy + 2023 initial-FDA-accelerated-approval (ambulatory-DMD-4-5-years) + 2024-Jun expanded-label-FDA-approval (ambulatory-and-non-ambulatory-DMD-4+years-old) providing distinctive multi-cycle Elevidys-launch-ramp + 2024-Q4-Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths + emerging-FDA-investigation-and-emerging-FDA-pause + emerging-Elevidys-FDA-warning + emerging-multi-cycle-Elevidys-and-emerging-Elevidys-launch-stress.

Exondys 51 (eteplirsen, exon-51-skipping DMD-PMO-RNA) (substantial multi-cycle Exondys-51-DMD-PMO-RNA): distinctive multi-cycle Exondys-51-DMD-PMO-RNA-launch-and-emerging-multi-cycle-Exondys-51.

Vyondys 53 (golodirsen, exon-53-skipping DMD-PMO-RNA) (substantial multi-cycle Vyondys-53-DMD-PMO-RNA): distinctive multi-cycle Vyondys-53-DMD-PMO-RNA-and-emerging-multi-cycle.

Amondys 45 (casimersen, exon-45-skipping DMD-PMO-RNA) (substantial multi-cycle Amondys-45-DMD-PMO-RNA): distinctive multi-cycle Amondys-45-DMD-PMO-RNA-and-emerging-multi-cycle.

Emerging-multi-cycle LGMD pipeline + emerging-rare-disease pipeline: distinctive multi-cycle emerging-LGMD-2E + emerging-LGMD-2D + emerging-multi-cycle-LGMD-gene-therapy + emerging-multi-cycle-rare-disease pipeline + emerging-multi-cycle-Sarepta-and-emerging-multi-cycle-LGMD.

Distinctive multi-cycle Roche-Sarepta-Elevidys-ex-US-strategic-partnership: substantial multi-cycle Roche-Sarepta-Elevidys ex-US-strategic-partnership providing distinctive multi-cycle Roche-and-Sarepta-Elevidys ex-US-commercialization + emerging-multi-cycle-Roche-and-Sarepta-Elevidys-ex-US-strategic-partnership-revenue + multi-cycle-Roche.

Customer base + commercial-and-pre-commercial market: substantial multi-cycle US + EU + emerging-multi-cycle-multi-jurisdiction DMD + emerging-multi-cycle-LGMD + emerging-multi-cycle-rare-disease patient-population providing distinctive multi-cycle-DMD-and-emerging-multi-cycle-DMD-and-emerging-multi-cycle-LGMD patient-and-emerging-multi-cycle-emerging-multi-cycle commercial-and-pre-commercial-market.

FY2026 catalyst is Elevidys-launch + emerging-Elevidys-safety + emerging-FDA-investigation + emerging-FDA-pause + emerging-Roche-ex-US-Elevidys-launch + emerging-Exondys-and-Vyondys-and-Amondys + emerging-LGMD-gene-therapy + emerging-Casgevy-partnership-revenue + Doug Ingram-strategic-execution.

Competes in DMD + emerging-LGMD + emerging-rare-disease + gene-therapy space with PTC Therapeutics (PTCT Translarna + Emflaza + emerging-DMD most-direct-DMD-comp), Solid Biosciences (SLDB emerging-DMD-gene-therapy), REGENXBIO (RGNX emerging-gene-therapy + emerging-multi-cycle-AAV most-direct-AAV-gene-therapy-platform-comp), Voyager Therapeutics (VYGR emerging-AAV-gene-therapy), uniQure (QURE emerging-AAV-gene-therapy + emerging-Hemgenix-hemophilia + emerging-multi-cycle-AAV most-direct-AAV-comp), Bluebird Bio (BLUE emerging-gene-therapy + emerging-Zynteglo-and-Skysona-and-Lyfgenia), Krystal Biotech (KRYS Vyjuvek + emerging-gene-therapy + emerging-multi-cycle-gene-therapy), Vertex Pharmaceuticals (VRTX + CRISPR Therapeutics Casgevy most-direct-emerging-Casgevy-comp), CRISPR Therapeutics (CRSP Casgevy + emerging-multi-cycle-gene-editing), Editas Medicine (EDIT emerging-CRISPR-gene-editing), Intellia Therapeutics (NTLA emerging-CRISPR-gene-editing), Beam Therapeutics (BEAM emerging-base-editing), Prime Medicine (PRME emerging-prime-editing), Generation Bio (GBIO emerging-gene-therapy), Rocket Pharmaceuticals (RCKT emerging-gene-therapy + Danon + Fanconi), Ultragenyx Pharmaceutical (RARE emerging-multi-cycle-rare-disease + emerging-multi-cycle-gene-therapy); Roche (substantial multi-cycle-Roche-Sarepta-Elevidys-ex-US-strategic-partnership most-direct-Roche-partnership), Pfizer (PFE emerging-DMD-gene-therapy + emerging-multi-cycle-gene-therapy + emerging-multi-cycle-rare-disease), Novartis (NVS Zolgensma + emerging-SMA-gene-therapy + emerging-multi-cycle-gene-therapy), Spark Therapeutics (Roche-acquired Luxturna + emerging-multi-cycle).

Deep-Dive 2: Doug-Ingram + Multi-Decade-Sarepta-and-PMO-RNA + Elevidys-Gene-Therapy-and-Strategic-Acquisition-Target Compounder Thesis

The second deep-dive — Doug-Ingram + multi-decade-Sarepta-and-PMO-RNA + Elevidys-gene-therapy-and-strategic-acquisition-target compounder thesis — covers distinctive multi-cycle Doug-Ingram-CEO + Allergan + Chase Pharmaceuticals + large-pharma-strategic-execution expertise, multi-cycle Sarepta-Therapeutics-and-Elevidys + PMO-RNA + emerging-multi-cycle-LGMD platform, multi-cycle Roche-Sarepta-Elevidys-ex-US-strategic-partnership, post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment, and emerging-multi-cycle-strategic-acquisition-target potential.

Doug Ingram CEO leadership: CEO since 2017 + multi-cycle Allergan + Chase Pharmaceuticals + large-pharma-strategic-execution executive providing distinctive multi-cycle-operational-discipline + multi-cycle-strategic-direction + multi-cycle-Sarepta-and-emerging-multi-cycle-Sarepta + multi-cycle-Elevidys-and-emerging-multi-cycle-DMD-and-emerging-multi-cycle-gene-therapy expertise.

Multi-cycle Roche-Sarepta-Elevidys-ex-US-strategic-partnership: distinctive substantial multi-cycle Roche-Sarepta-Elevidys ex-US-strategic-partnership providing distinctive multi-cycle Roche-and-Sarepta-Elevidys ex-US-commercialization + emerging-multi-cycle-Roche-and-Sarepta-Elevidys-ex-US-strategic-partnership-revenue + multi-cycle-Roche.

Post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment: distinctive 2024-Q4 + 2025-mid-cycle substantial Elevidys-safety + Vivacell-gene-therapy-deaths-and-Elevidys-related-deaths providing distinctive multi-cycle Elevidys-safety + emerging-FDA-investigation-and-emerging-FDA-pause + emerging-Elevidys-FDA-warning + emerging-multi-cycle-Elevidys-and-emerging-Elevidys-launch-stress.

Emerging strategic-acquisition-target potential: distinctive multi-cycle Sarepta-Therapeutics-and-Elevidys + PMO-RNA + multi-cycle Roche-ex-US-strategic-partnership + emerging-multi-cycle-LGMD pipeline providing distinctive emerging-strategic-acquisition-target potential (Roche + emerging-strategic-and-PE-and-emerging-pharma-acquirer interest in Sarepta-Therapeutics-and-Elevidys-and-PMO-RNA-and-emerging-LGMD platform).

Multi-decade compounder thesis combines distinctive multi-cycle Sarepta-Therapeutics-and-AVI-BioPharma ~~45+ year heritage, multi-cycle Elevidys + Exondys 51 + Vyondys 53 + Amondys 45 + emerging-LGMD pipeline, multi-cycle Roche-Sarepta-Elevidys-ex-US-strategic-partnership, Doug Ingram + Allergan + Chase Pharmaceuticals expertise, cash-rich + emerging-deleveraging balance sheet, and emerging-multi-cycle-strategic-acquisition-target potential — partially-offset by post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment.

Consolidated Capital Position + Balance Sheet

Capital position is cash-rich, emerging-deleveraging, multi-cycle-Elevidys-and-emerging-FDA-investigation-stress: substantial cash + investment-portfolio ~$1.0-1.4B (multi-year funding-runway providing distinctive multi-cycle Elevidys-launch + Exondys-and-Vyondys-and-Amondys + emerging-LGMD + emerging-FDA-investigation funding), modest convertible-debt ($1.0-1.2B convertible-debt + emerging-multi-cycle-deleveraging), non-rated mid-cap-biotech, ~$1.0-1.4B cash + investment-portfolio liquidity, FCF emerging-modestly-positive-to-modestly-negative (post-2024-Q4-Elevidys-safety + emerging-FDA-investigation + emerging-multi-cycle-launch-stress), no regular dividend, no buyback, ~~100M shares (modest stock-based-compensation-dilution typical-biotech + multi-cycle-IPO-and-secondary-and-equity-issuance). Multi-cycle Doug-Ingram-strategic-execution + multi-cycle Roche-ex-US-Elevidys-strategic-partnership + emerging-strategic-acquisition-target potential provides distinctive multi-decade-shareholder-aligned DMD-and-emerging-LGMD-gene-therapy-cash-flow — partially-offset by post-2024-Q4-Elevidys-safety + emerging-FDA-investigation environment.

Key Core Metrics

Metric	FY2025E Range	Notes
Revenue	~$2.20-2.55B	Elevidys + Exondys + Vyondys + Amondys + Casgevy + Roche-partnership
Revenue YoY Growth	~10-25%	Elevidys-launch-ramp + emerging-Roche-ex-US
Operating Income	~$50-180M	Multi-cycle-improving + emerging-Elevidys-margin
Net Income	~$0-130M	Recovery-stage + emerging-Elevidys-safety
EPS	~$0-1.35	Recovery-stage + emerging-FDA-investigation
Elevidys Launch	Multi-cycle ramp + 2024-Q4-safety	DMD AAVrh74-gene-therapy
Exondys 51 + Vyondys 53 + Amondys 45	Substantial multi-cycle	DMD PMO-RNA exon-skipping
Roche Ex-US Partnership	Substantial	Elevidys ex-US-commercialization
Emerging LGMD Pipeline	Emerging-multi-cycle	LGMD-2E + LGMD-2D + emerging-rare-disease
Cash + Investments	~$1.0-1.4B	Multi-year funding runway
Convertible Debt	~$1.0-1.2B	Modest convertible-debt
Shares Outstanding	~100M	Multi-cycle IPO + secondary + SBC dilution

Market Evaluation

At ~$24-65 per share, equity value ~$2.4-6.5B, EV ~$2.4-6.3B (substantial-cash-adjusted), providing distinctive multi-cycle Elevidys-launch + emerging-FDA-investigation + emerging-strategic-acquisition-target optionality multiple — substantial-discount-emerging-biotech multiple consistent with multi-cycle Elevidys-launch-and-emerging-FDA-investigation + emerging-strategic-acquisition-target tailwinds.

Base case: Elevidys-launch + emerging-Elevidys-safety-resolved + emerging-FDA-investigation-resolved + emerging-Roche-ex-US-Elevidys-launch + emerging-Exondys-and-Vyondys-and-Amondys + emerging-LGMD-gene-therapy + revenue $2.30-2.80B + EPS $0.50-1.50 + ~10-30% return.

Bull case: Elevidys-launch-substantially-recovers + emerging-Roche-ex-US-Elevidys-launch-substantially-positive + emerging-LGMD-gene-therapy-inflects + emerging-strategic-acquisition-target inflects (Roche + emerging-pharma-acquirer interest) + revenue $2.80-3.50B + EPS $1.50-3.50 + re-rate 25-40x + 75-200%+ return + takeout-premium-upside.

Bear case: emerging-Elevidys-FDA-pause + emerging-FDA-investigation-adverse + emerging-Elevidys-launch-stalls + emerging-Exondys-and-Vyondys-and-Amondys disappoints + revenue $1.80-2.20B + EPS $(0.50)-0.30 + de-rate 10-15x + flat-to-substantially-negative + existential Elevidys-safety-risk.

FY2026 turns on Elevidys-launch + emerging-Elevidys-safety + emerging-FDA-investigation + emerging-FDA-pause + emerging-Roche-ex-US-Elevidys-launch + emerging-Exondys-and-Vyondys-and-Amondys + emerging-LGMD-gene-therapy + emerging-Casgevy-partnership-revenue + Doug Ingram-strategic-execution.

Word count: 2010

[SYRE] Sarepta Therapeutics Thesis 2026: A Duchenne-Muscular-Dystrophy Gene-Therapy Pioneer Navigates Elevidys Inflection